Sunday, December 18, 2022 12:45:05 PM
I could imagine so. The crazy thing here is (CUSIP) was setup to go into effect post split correct? That is how the CEO explained it to Lou on a call. Was it the CEO actually speaking (no clue) but you would hope so. No telling nowadays. So instead of being haulted it traded again as COSM. I remember some thinking it might not trade for s few days until all settlements were sorted out but they ran it anyways. Either my understanding of the process is way wrong or someone was trying to pull a fast one. Cause it’s technically separated into two tickers now.
If my understanding is off my apologies in advance
If my understanding is off my apologies in advance
Recent COSM News
- Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657 • GlobeNewswire Inc. • 06/01/2026 12:25:00 PM
- Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation • GlobeNewswire Inc. • 05/26/2026 01:34:16 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 08:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 01:30:32 PM
- Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants • ACCESS Newswire • 05/21/2026 06:20:00 PM
- Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway • ACCESS Newswire • 05/21/2026 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:31:01 PM
- Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Prog • ACCESS Newswire • 05/14/2026 01:00:00 PM
- Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 • ACCESS Newswire • 05/12/2026 02:15:00 PM
- Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months • ACCESS Newswire • 05/11/2026 06:25:00 PM
- Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness • ACCESS Newswire • 05/06/2026 02:35:00 PM
- Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months • ACCESS Newswire • 04/30/2026 04:50:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/25/2026 12:33:19 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:30:45 PM
- Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products • ACCESS Newswire • 04/21/2026 04:50:00 PM
- Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio • ACCESS Newswire • 04/20/2026 02:55:00 PM
- Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health • ACCESS Newswire • 04/17/2026 06:00:00 PM
- Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% • ACCESS Newswire • 04/16/2026 07:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 03:15:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:34:41 PM
- Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 20 • ACCESS Newswire • 04/15/2026 01:25:00 PM
- Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units • ACCESS Newswire • 04/13/2026 04:50:00 PM
- Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months • ACCESS Newswire • 04/10/2026 01:40:00 PM
- Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction • ACCESS Newswire • 04/08/2026 03:10:00 PM
